<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39254826</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-187X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>American journal of cardiovascular drugs : drugs, devices, and other interventions</Title><ISOAbbreviation>Am J Cardiovasc Drugs</ISOAbbreviation></Journal><ArticleTitle>Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients with Venous Thromboembolism using Real-World Data: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40256-024-00677-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Direct oral anticoagulants (DOACs) have shown comparable efficacy and a superior safety profile in clinical trials for patients with venous thromboembolism (VTE). However, further study is needed to assess DOACs' effectiveness and safety compared to warfarin in a real-world context. Thus, this meta-analysis compares the effectiveness and safety of warfarin and DOACs in patients with VTE.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A systematic review of the literature using PubMed and EMBASE was conducted from inception until June 2024. We examined observational studies that compared safety and effectiveness between DOACs and warfarin when used in treating VTE and reported adjusted hazard ratios (HRs) and/or odds ratios (ORs) for recurrent VTE, major bleeding, clinically relevant non-major bleeding, gastrointestinal bleeding, intracranial hemorrhage, and death from any cause. We then estimated the pooled effect using the random-effects model for meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 25 studies were included in the current meta-analysis. DOAC therapy was associated with significantly lower risks of recurrent VTE (HR 0.76, 95% confidence interval [CI] 0.69-0.85), major bleeding (HR 0.77, 95% CI 0.72-0.83), clinically relevant non-major bleeding (HR 0.82, 95% CI 0.77-0.88), and gastrointestinal bleeding (HR 0.75, 95% CI 0.68-0.83) compared to warfarin. However, no statistically significant difference was observed in all-cause mortality between the two groups (HR 0.96, 95% CI 0.83-1.10).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This meta-analysis found that DOACs are associated with a significant reduction in VTE recurrence in addition to the known favorable safety profile when compared to warfarin.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alshahrani</LastName><ForeName>Walaa A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Alshahrani</LastName><ForeName>Razan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkathiri</LastName><ForeName>Munirah A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alay</LastName><ForeName>Saeed M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alabkka</LastName><ForeName>Abdulrahman M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alaraj</LastName><ForeName>Saleh A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Yami</LastName><ForeName>Majed S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altayyar</LastName><ForeName>Waad A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfayez</LastName><ForeName>Osamah M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia. oalfayez@qu.edu.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basoodan</LastName><ForeName>Manar S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Almutairi</LastName><ForeName>Abdulaali R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almohammed</LastName><ForeName>Omar A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Am J Cardiovasc Drugs</MedlineTA><NlmUniqueID>100967755</NlmUniqueID><ISSNLinking>1175-3277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39254826</ArticleId><ArticleId IdType="doi">10.1007/s40256-024-00677-x</ArticleId><ArticleId IdType="pii">10.1007/s40256-024-00677-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Day ISCfWT. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014; 12:1580–1590. https://doi.org/10.1111/jth.12698 .</Citation></Reference><Reference><Citation>Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388:3060–73. https://doi.org/10.1016/s0140-6736(16)30514-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(16)30514-1</ArticleId><ArticleId IdType="pubmed">27375038</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011;86:217–20. https://doi.org/10.1002/ajh.21917 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.21917</ArticleId><ArticleId IdType="pubmed">21264912</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20:248–62. https://doi.org/10.1038/s41569-022-00787-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-022-00787-6</ArticleId><ArticleId IdType="pubmed">36258120</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepassi A, Chingcuanco F, Gordon R, Meier A, Divino V, DeKoven M, et al. Resource utilization and charges of patients with and without diagnosed venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study. J Med Econ. 2018;21:595–602. https://doi.org/10.1080/13696998.2018.1445635 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2018.1445635</ArticleId><ArticleId IdType="pubmed">29480088</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombol. 2016;41:187–205. https://doi.org/10.1007/s11239-015-1319-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1319-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;41:543–603. https://doi.org/10.1093/eurheartj/ehz405 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz405</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack T, Harrisingh MC, Horner D, Bewley S. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ. 2020;369: m1565. https://doi.org/10.1136/bmj.m1565 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1565</ArticleId><ArticleId IdType="pubmed">32430311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–738. https://doi.org/10.1182/bloodadvances.2020001830 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001830</ArticleId><ArticleId IdType="pubmed">33007077</ArticleId><ArticleId IdType="pmc">7556153</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:2247–59. https://doi.org/10.1016/j.chest.2021.07.056 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.07.056</ArticleId><ArticleId IdType="pubmed">34352279</ArticleId></ArticleIdList></Reference><Reference><Citation>Piran S, Schulman S. Management of venous thromboembolism: an update. Thromb J. 2016;14:23. https://doi.org/10.1186/s12959-016-0107-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-016-0107-z</ArticleId><ArticleId IdType="pubmed">27766049</ArticleId><ArticleId IdType="pmc">5056465</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52. https://doi.org/10.1056/NEJMoa0906598 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0906598</ArticleId><ArticleId IdType="pubmed">19966341</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72. https://doi.org/10.1161/CIRCULATIONAHA.113.004450 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.004450</ArticleId><ArticleId IdType="pubmed">24344086</ArticleId></ArticleIdList></Reference><Reference><Citation>The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510. https://doi.org/10.1056/NEJMoa1007903 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1007903</ArticleId></ArticleIdList></Reference><Reference><Citation>The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med. 2012;366:1287–1297. https://doi.org/10.1056/NEJMoa1113572 .</Citation></Reference><Reference><Citation>Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. https://doi.org/10.1056/NEJMoa1302507 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1302507</ArticleId><ArticleId IdType="pubmed">23808982</ArticleId></ArticleIdList></Reference><Reference><Citation>The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15. https://doi.org/10.1056/NEJMoa1306638 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1306638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https://doi.org/10.1186/s13643-016-0384-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId><ArticleId IdType="pmc">5139140</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10(1):83–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1316</ArticleId><ArticleId IdType="pubmed">30067315</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787–8. https://doi.org/10.1001/jamasurg.2021.0522 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2021.0522</ArticleId><ArticleId IdType="pubmed">33825847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000.</Citation></Reference><Reference><Citation>Basto AN, Fewel NP, Vo K, Stock EM, Ta M. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. J Thromb Thrombol. 2018;45:51–5. https://doi.org/10.1007/s11239-017-1578-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-017-1578-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman CI, Bunz TJ, Turpie AGG. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost. 2017;117:1841–7. https://doi.org/10.1160/th17-03-0210 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th17-03-0210</ArticleId><ArticleId IdType="pubmed">28640322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun M, Lix LM, Durand M, Dahl M, Paterson JM, Dormuth CR, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017;359: j4323. https://doi.org/10.1136/bmj.j4323 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j4323</ArticleId><ArticleId IdType="pubmed">29042362</ArticleId><ArticleId IdType="pmc">5641962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindet-Pedersen C, Langtved Pallisgaard J, Staerk L, Gerds TA, Fosbøl EL, Torp-Pedersen C, et al. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study. Thromb Haemost. 2017;117:1182–91. https://doi.org/10.1160/th16-10-0745 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th16-10-0745</ArticleId><ArticleId IdType="pubmed">28300865</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen TB, Skjøth F, Kjældgaard JN, Lip GYH, Nielsen PB, Søgaard M. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematol. 2017;4:e237–44. https://doi.org/10.1016/s2352-3026(17)30054-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-3026(17)30054-6</ArticleId><ArticleId IdType="pubmed">28411120</ArticleId></ArticleIdList></Reference><Reference><Citation>Badreldin H. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. J Thromb Thrombol. 2018;46:16–21. https://doi.org/10.1007/s11239-018-1661-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1661-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, MacLehose RF. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. Thromb Haemost. 2018;118:1637–45. https://doi.org/10.1055/s-0038-1668521 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1668521</ArticleId><ArticleId IdType="pubmed">30103250</ArticleId><ArticleId IdType="pmc">6172009</ArticleId></ArticleIdList></Reference><Reference><Citation>Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. Clinical Practice. Thromb Haemost. 2018;118:1951–61. https://doi.org/10.1055/s-0038-1673689 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1673689</ArticleId><ArticleId IdType="pubmed">30357780</ArticleId><ArticleId IdType="pmc">6206509</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khateep YM, Zaid NA, Salim OR. Comparative study of safety and effectiveness of rivaroxaban and warfarin in patients with acute deep venous thrombosis. Egypt J Surg. 2019;38:245–9.</Citation></Reference><Reference><Citation>Costa OS, Thompson S, Ashton V, Palladino M, Bunz TJ, Coleman CI. Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis. Thromb J. 2020;18:6. https://doi.org/10.1186/s12959-020-00219-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-020-00219-w</ArticleId><ArticleId IdType="pubmed">32292291</ArticleId><ArticleId IdType="pmc">7140368</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020;77:188–95. https://doi.org/10.1093/ajhp/zxz307 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajhp/zxz307</ArticleId><ArticleId IdType="pubmed">31974557</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Duan L, He W, Hong C, Guo Y, Wang X, et al. Efficacy and safety of rivaroxaban versus warfarin for the treatment of acute pulmonary embolism: a real-world study. Anal Cell Pathol (Amst). 2020;2020:6813492. https://doi.org/10.1155/2020/6813492 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/6813492</ArticleId><ArticleId IdType="pubmed">32676276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Fang CC, Tsai LM, Lin HW, Chen PS, Lin SH, et al. Changing treatment patterns in patients with venous thromboembolism in Taiwan. Circ J. 2020;84:283–93. https://doi.org/10.1253/circj.CJ-19-0741 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-19-0741</ArticleId><ArticleId IdType="pubmed">31932560</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi I, Talib A, Nayema R, Syed M, Ghazanfar R, Fatima S. Length of hospital stay in treatment of venous thromboembolism: do outcomes vary preference of anticoagulant? A retrospective analysis. Acta Haematol Polon. 2021;52:590–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/AHP.a2021.0085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakai NA, Walker RF, MacLehose RF, Koh I, Alonso A, Lutsey PL. Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis. Res Pract Thromb Haemost. 2021;5: e12575. https://doi.org/10.1002/rth2.12575 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12575</ArticleId><ArticleId IdType="pubmed">34430789</ArticleId><ArticleId IdType="pmc">8371351</ArticleId></ArticleIdList></Reference><Reference><Citation>Perino AC, Fan J, Schmitt S, Guo JD, Hlavacek P, Din N, et al. Anticoagulation treatment and outcomes of venous thromboembolism by weight and body mass index: insights from the veterans health administration. Circ Cardiovasc Qual Outcomes. 2021;14: e008005. https://doi.org/10.1161/circoutcomes.121.008005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circoutcomes.121.008005</ArticleId><ArticleId IdType="pubmed">34724801</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham A, Heib A, Goodman E, Cotto R, Jafari P, Lipsitz E, et al. Warfarin versus direct oral anticoagulants for patients needing distal deep vein thrombosis treatment. J Vasc Surg Venous Lymphat Disord. 2022;10:826-831.e821. https://doi.org/10.1016/j.jvsv.2022.01.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2022.01.006</ArticleId><ArticleId IdType="pubmed">35124243</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Sah J, Dhamane AD, Hines DM, Lee T, Rosenblatt L, et al. Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences. Adv Ther. 2023;40:1705–35. https://doi.org/10.1007/s12325-023-02440-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-023-02440-1</ArticleId><ArticleId IdType="pubmed">36811795</ArticleId><ArticleId IdType="pmc">10070226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingason AB, Hreinsson JP, Agustsson AS, Lund SH, Rumba E, Palsson DA, et al. Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared with direct oral anticoagulants: a population-based propensity-weighted cohort study. Clin Gastroenterol Hepatol. 2023;21:347-357.e310. https://doi.org/10.1016/j.cgh.2022.06.033 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.06.033</ArticleId><ArticleId IdType="pubmed">35977616</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JD, Rajpura J, Hlavacek P, Keshishian A, Sah J, Delinger R, et al. Comparative clinical and economic outcomes associated with warfarin versus apixaban in the treatment of patients with venous thromboembolism in a large U.S. Commercial Claims Database. J Manag Care Spec Pharm. 2020;26:1017–26. https://doi.org/10.1855/jmcp.2020.19311 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1855/jmcp.2020.19311</ArticleId><ArticleId IdType="pubmed">32452277</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JD, Hlavacek P, Rosenblatt L, Keshishian A, Russ C, Mardekian J, et al. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. Thromb Res. 2021;198:163–70. https://doi.org/10.1016/j.thromres.2020.11.039 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.11.039</ArticleId><ArticleId IdType="pubmed">33348190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI. Comparative risk of major bleeding with rivaroxaban and warfarin: population-based cohort study of unprovoked venous thromboembolism. Eur J Haematol. 2019;102:143–9. https://doi.org/10.1111/ejh.13185 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13185</ArticleId><ArticleId IdType="pubmed">30328143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Isaza E, Tuta-Quintero E, Bastidas-Goyes A, et al. Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin—propensity score matching study. BMC Pharmacol Toxicol. 2023;24:77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-023-00712-8</ArticleId><ArticleId IdType="pubmed">38093310</ArticleId><ArticleId IdType="pmc">10720047</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang MC, Reynolds K, Fan D, et al. Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism. JAMA Netw Open. 2023;6(8): e2328033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.28033</ArticleId><ArticleId IdType="pubmed">37581888</ArticleId><ArticleId IdType="pmc">10427945</ArticleId></ArticleIdList></Reference><Reference><Citation>Glise Sandblad K, Schulman S, Rosengren A, Sörbo J, Philipson J, Hansson P-O. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—a nationwide register-based study. J Intern Med. 2023;294:743–60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13712</ArticleId><ArticleId IdType="pubmed">37641391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21:1–386. https://doi.org/10.3310/hta21090 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta21090</ArticleId><ArticleId IdType="pubmed">28738015</ArticleId><ArticleId IdType="pmc">5534974</ArticleId></ArticleIdList></Reference><Reference><Citation>Senoo K, Kondo Y, Miyazawa K, Isogai T, Chun YH, Kobayashi Y. Safety and efficacy of direct oral anticoagulants over warfarin in Japanese patients with acute venous thromboembolism: a meta-analysis. J Cardiol. 2017;69:763–8. https://doi.org/10.1016/j.jjcc.2016.07.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2016.07.007</ArticleId><ArticleId IdType="pubmed">27502316</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitelzweig S, Bergrath E, Fusco MD, Kang A, Savone M, Cappelleri JC, et al. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. Future Cardiol. 2022;18:393–405. https://doi.org/10.2217/fca-2021-0120 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fca-2021-0120</ArticleId><ArticleId IdType="pubmed">35360925</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Yami MS, Alzahrani MY, Alshehri AM, Alshaya OA, Alsubiae NS, Alharbi YM, et al. Real-world effectiveness and safety of apixaban versus warfarin in patients with acute venous thromboembolism: experience of a large tertiary hospital in Saudi Arabia. Int J Gen Med. 2021;14:4031–7. https://doi.org/10.2147/ijgm.S322221 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ijgm.S322221</ArticleId><ArticleId IdType="pubmed">34349553</ArticleId><ArticleId IdType="pmc">8327475</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, et al. Hospital resource utilization and costs associated with warfarin versus apixaban treatment among patients hospitalized for venous thromboembolism in the United States. Clin Appl Thromb Hemost. 2018;24:261s–8s. https://doi.org/10.1177/1076029618800806 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029618800806</ArticleId><ArticleId IdType="pubmed">30433823</ArticleId><ArticleId IdType="pmc">6714861</ArticleId></ArticleIdList></Reference><Reference><Citation>Memon RA, Hamdani SSQ, Usama A, Aisha F, Kundi H, Mathavan M, et al. Comparison of the efficacy and safety of apixaban and warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Cureus. 2022;14: e27838. https://doi.org/10.7759/cureus.27838 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.27838</ArticleId><ArticleId IdType="pubmed">36134060</ArticleId><ArticleId IdType="pmc">9481239</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Song D, Wang L, Wang C, Zhou J, Sun J, et al. Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: a meta-analysis. Front Surg. 2023;10:1086871. https://doi.org/10.3389/fsurg.2023.1086871 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fsurg.2023.1086871</ArticleId><ArticleId IdType="pubmed">37139185</ArticleId><ArticleId IdType="pmc">10149967</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryal MR, Gosain R, Donato A, Yu H, Katel A, Bhandari Y, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3:2381–7. https://doi.org/10.1182/bloodadvances.2019000572 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000572</ArticleId><ArticleId IdType="pubmed">31405948</ArticleId><ArticleId IdType="pmc">6693001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>